ENTITY

Stille (STIL SF)

12
Analysis
Health Care • Sweden
Stille AB is a Sweden-based company that develops, manufactures, and markets medical devices. The company operates through two business segments: Surgical Instruments and Surgical Tables. The Surgical Instruments segment provides a variety of handcrafted, forged surgical instruments for open surgery, with a focus on cardiovascular, and reconstructive and aesthetic plastic surgery. Its products include scissors, forceps, clamps, and retractors. The Surgical Tables segment, also referred to as Patient Positioning, develops and manufactures specialized procedure-specific tables for cardiovascular surgery, gynecology, and urology.
more
bullish•Stille
•09 Oct 2026 17:20•Syndicated

Stille (Q3 preview): Sustained growth with margins holding up

Redeye provides a preview of its estimates ahead of Stille's Q3 2026 results. We expect continued strong sales growth, supported by the...

Logo
Redeye
73 Views
Share
bearish•Stille
•24 Jul 2026 13:55•Syndicated

Stille (Q2 review): Closing a solid H1 with intact momentum

Stille's Q2 painted a picture of continued sales momentum (+8% vs. REe) and an encouraging outlook for delivering on the order backlog following...

Logo
Redeye
109 Views
Share
bullish•Stille
•23 Jul 2026 14:51•Syndicated

Stille (Q2 initial take): Sales beat with softer margins

Stille's Q2 2026 report beat our estimates on sales by ~7%, but showed softer margins than we had pencilled in, with EBIT margin of 15% versus our...

Logo
Redeye
107 Views
Share
bullish•Stille
•20 Jul 2026 17:37•Syndicated

Stille (Q2 preview): Intact momentum with fading headwinds?

Redeye provides a preview of its estimates ahead of Stille's Q2 results, scheduled for release on July 23. We expect a report continuing on Q1's...

Logo
Redeye
113 Views
Share
bullish•Stille
•28 Apr 2026 13:55•Syndicated

Stille (Q1 Review): Starting 2026 in style with momentum expected to continue

Stille delivered a Q1 ahead of our estimates across the board, with 19% organic growth and a 21.5% EBITDA margin. The conference call reinforced...

Logo
Redeye
106 Views
Share
x